185 related articles for article (PubMed ID: 9616230)
1. Inhibition of mesangial cell proliferation by E2F decoy oligodeoxynucleotide in vitro and in vivo.
Maeshima Y; Kashihara N; Yasuda T; Sugiyama H; Sekikawa T; Okamoto K; Kanao K; Watanabe Y; Kanwar YS; Makino H
J Clin Invest; 1998 Jun; 101(11):2589-97. PubMed ID: 9616230
[TBL] [Abstract][Full Text] [Related]
2. An oligonucleotide decoy for transcription factor E2F inhibits mesangial cell proliferation in vitro.
Tomita N; Horiuchi M; Tomita S; Gibbons GH; Kim JY; Baran D; Dzau VJ
Am J Physiol; 1998 Aug; 275(2):F278-84. PubMed ID: 9691019
[TBL] [Abstract][Full Text] [Related]
3. Gene therapy with an E2F transcription factor decoy inhibits cell cycle progression in rat anti-Thy 1 glomerulonephritis.
Tomita N; Kim JY; Gibbons GH; Zhang L; Kaneda Y; Stahl RA; Ogborn M; Venderville B; Morishita R; Baran D; Dzau VJ
Int J Mol Med; 2004 May; 13(5):629-36. PubMed ID: 15067361
[TBL] [Abstract][Full Text] [Related]
4. Inhibitory effects of novel E2F decoy oligodeoxynucleotides on mesangial cell proliferation by coexpression of E2F/DP.
Park KK; Deok Ahn J; Lee IK; Magae J; Heintz NH; Kwak JY; Lee YC; Cho YS; Kim HC; Chae YM; Ho Kim Y; Kim CH; Chang YC
Biochem Biophys Res Commun; 2003 Sep; 308(4):689-97. PubMed ID: 12927774
[TBL] [Abstract][Full Text] [Related]
5. A gene therapy strategy using a transcription factor decoy of the E2F binding site inhibits smooth muscle proliferation in vivo.
Morishita R; Gibbons GH; Horiuchi M; Ellison KE; Nakama M; Zhang L; Kaneda Y; Ogihara T; Dzau VJ
Proc Natl Acad Sci U S A; 1995 Jun; 92(13):5855-9. PubMed ID: 7597041
[TBL] [Abstract][Full Text] [Related]
6. Roles of E2F1 in mesangial cell proliferation in vitro.
Inoshita S; Terada Y; Nakashima O; Kuwahara M; Sasaki S; Marumo F
Kidney Int; 1999 Dec; 56(6):2085-95. PubMed ID: 10594784
[TBL] [Abstract][Full Text] [Related]
7. Suppression of proliferative cholangitis by E2F decoy oligodeoxynucleotide.
Yoshida M; Yamamoto N; Nitta T; Uehara T; Terao R; Hatano E; Iimuro Y; Yamaoka Y
J Surg Res; 2002 Feb; 102(2):95-101. PubMed ID: 11796004
[TBL] [Abstract][Full Text] [Related]
8. Three-dimensional matrix suppresses E2F-controlled gene expression in glomerular mesangial cells.
Tsuboi N; Yoshida H; Kawamura T; Furukawa Y; Hosoya T; Yamada H
Kidney Int; 2000 Apr; 57(4):1581-9. PubMed ID: 10760093
[TBL] [Abstract][Full Text] [Related]
9. Ex-vivo gene therapy of human vascular bypass grafts with E2F decoy: the PREVENT single-centre, randomised, controlled trial.
Mann MJ; Whittemore AD; Donaldson MC; Belkin M; Conte MS; Polak JF; Orav EJ; Ehsan A; Dell'Acqua G; Dzau VJ
Lancet; 1999 Oct; 354(9189):1493-8. PubMed ID: 10551494
[TBL] [Abstract][Full Text] [Related]
10. Long-term stabilization of vein graft wall architecture and prolonged resistance to experimental atherosclerosis after E2F decoy oligonucleotide gene therapy.
Ehsan A; Mann MJ; Dell'Acqua G; Dzau VJ
J Thorac Cardiovasc Surg; 2001 Apr; 121(4):714-22. PubMed ID: 11279413
[TBL] [Abstract][Full Text] [Related]
11. Growth inhibition of cultured human Tenon's fibroblastic cells by targeting the E2F transcription factor.
Akimoto M; Hangai M; Okazaki K; Kogishi J; Honda Y; Kaneda Y
Exp Eye Res; 1998 Oct; 67(4):395-401. PubMed ID: 9820786
[TBL] [Abstract][Full Text] [Related]
12. E2F decoy oligodeoxynucleotides effectively inhibit growth of human tumor cells.
Ahn JD; Kim CH; Magae J; Kim YH; Kim HJ; Park KK; Hong S; Park KG; Lee IK; Chang YC
Biochem Biophys Res Commun; 2003 Oct; 310(4):1048-53. PubMed ID: 14559221
[TBL] [Abstract][Full Text] [Related]
13. Gene therapy for attenuating cardiac allograft arteriopathy using ex vivo E2F decoy transfection by HVJ-AVE-liposome method in mice and nonhuman primates.
Kawauchi M; Suzuki J; Morishita R; Wada Y; Izawa A; Tomita N; Amano J; Kaneda Y; Ogihara T; Takamoto S; Isobe M
Circ Res; 2000 Nov; 87(11):1063-8. PubMed ID: 11090553
[TBL] [Abstract][Full Text] [Related]
14. Sp1-decoy oligodeoxynucleotide inhibits high glucose-induced mesangial cell proliferation.
Chae YM; Park KK; Magae J; Lee IS; Kim CH; Kim HC; Hong S; Lee JG; Choi IJ; Kim HS; Min KS; Lee IK; Chang YC
Biochem Biophys Res Commun; 2004 Jun; 319(2):550-5. PubMed ID: 15178441
[TBL] [Abstract][Full Text] [Related]
15. Novel E2F decoy oligodeoxynucleotides inhibit in vitro vascular smooth muscle cell proliferation and in vivo neointimal hyperplasia.
Ahn JD; Morishita R; Kaneda Y; Kim HS; Chang YC; Lee KU; Park JY; Lee HW; Kim YH; Lee IK
Gene Ther; 2002 Dec; 9(24):1682-92. PubMed ID: 12457282
[TBL] [Abstract][Full Text] [Related]
16. Regulation of the G1/S transition phase in mesangial cells by E2F1.
Inoshita S; Terada Y; Nakashima O; Kuwahara M; Sasaki S; Marumo F
Kidney Int; 1999 Oct; 56(4):1238-41. PubMed ID: 10504464
[TBL] [Abstract][Full Text] [Related]
17. Glucocorticoids stimulate p21(CIP1) in mesangial cells and in anti-GBM glomerulonephritis.
Terada Y; Okado T; Inoshita S; Hanada S; Kuwahara M; Sasaki S; Yamamoto T; Marumo F
Kidney Int; 2001 May; 59(5):1706-16. PubMed ID: 11318941
[TBL] [Abstract][Full Text] [Related]
18. E2F-1 induces proliferation-specific genes and suppresses squamous differentiation-specific genes in human epidermal keratinocytes.
Dicker AJ; Popa C; Dahler AL; Serewko MM; Hilditch-Maguire PA; Frazer IH; Saunders NA
Oncogene; 2000 Jun; 19(25):2887-94. PubMed ID: 10871839
[TBL] [Abstract][Full Text] [Related]
19. A new member of the DP family, DP-3, with distinct protein products suggests a regulatory role for alternative splicing in the cell cycle transcription factor DRTF1/E2F.
Ormondroyd E; de la Luna S; La Thangue NB
Oncogene; 1995 Oct; 11(8):1437-46. PubMed ID: 7478568
[TBL] [Abstract][Full Text] [Related]
20. Changes in E2F complexes containing retinoblastoma protein family members and increased cyclin-dependent kinase inhibitor activities during terminal differentiation of cardiomyocytes.
Flink IL; Oana S; Maitra N; Bahl JJ; Morkin E
J Mol Cell Cardiol; 1998 Mar; 30(3):563-78. PubMed ID: 9515032
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
